Morschhauser F, Fowler NH, Feugier P, et al. RELEVANCE: phase III efficacy and safety study of lenalidomide plus rituximab (R2) versus rituximab plus chemotherapy, followed by rituximab, in previously untreated follicular lymphoma. EHA 2018; abstract S154.
T-cellymfoom na CAR T-celtherapie zeldzaam; genetische modificatie van cellen niet altijd de oorzaak
nov 2024 | Lymfoom